The effect of hepatitis C treatment response on medical costs: A longitudinal analysis in an integrated care setting

Journal of Managed Care Pharmacy

Volumn 19, Issue 6, 2013, Pages 438-447

  Manos, M Michele ^a   Darbinian, Jeanne ^b   Rubin, Jaime ^c   Ray, G Thomas ^b   Shvachko, Valentina ^b   Denis, Baris ^c   Velez, Fulton ^c   Quesenberry, Charles ^b  

^a Viral Hepatitis Registry   (United States)

^b DIVISION OF RESEARCH   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; AGE; AMERICAN INDIAN; ANTIVIRAL THERAPY; ARTICLE; ASIAN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; GENDER; GENOTYPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT; RACE; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84884146678     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.6.438     Document Type: Article

References (38)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556-62.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-14.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-21.
4. Colvin HM, Mitchell AE, eds. Committee on the Prevention and Control of Viral Hepatitis Infections, Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press; 2010:4.
5. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR. 2012;61(RR04):1-32.
6. Jacobson IM, Davis GL, El-Serag H, Negro F, Trepo C. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8(11):924-33; quiz e117.
7. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17(7):531-46.
8. Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98(9):2060-63.
9. HHS. 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. Available at: http://optn.transplant. hrsa.gov/ar2009/. Accessed April 24, 2013.
10. NIH. Management of hepatitis C. Paper presented at: National Institutes of Health Consensus Conference; June 10-12, 2002; Bethesda, MD.
11. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001;161(18):2231-37.
12. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90(10):1562-69.
13. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45(2):e17-24.
14. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
15. Fujiwara K, Allison RD, Wang RY, et al. Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology. 2013;57(2):483-91.
16. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139(5):1593-601.
17. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833-44.
18. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509-16, e501.
19. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45(3):579-87.
20. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677-84.
21. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280-88.
22. Manos MM, Zhao W, Shvachko VA. HCV-genotype-specific influences on incident diabetes: the effect of sustained viral response to antiviral therapy. Hepatology. 2009;50(4):358A.
23. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49(3):739-44.
24. Campos NG, Salomon JA, Servoss JC, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007;120(3):272-79.
25. Malone DC, Tran TT, Poordad FF. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag Care Pharm. 2005;11(8):687-94.
26. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290(2):228-37.
27. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24(7):661-72.
28. Solomon M, Bonafede M, Pan K, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011;56(10):3024-31.
29. Gordon N. Similarity of the adult Kaiser Permanente membership in northern California to the insured and general population in northern California: statistics from the 2007 California Health Interview Survey. Internal Report: Kaiser Permanente Division of Research; 2012.
30. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82(5):703-10.
31. Karter AJ, Schillinger D, Adams AS, et al. Elevated rates of diabetes in Pacific Islanders and Asian subgroups: the Diabetes Study of Northern California (DISTANCE). Diabetes Care. 2013;36(3):574-79.
32. Otani K, Baden WW. Healthcare cost and predictive factors: high- and low-utilization model development. Health Mark Q. 2009;26(3):198-208.
33. Meenan RT, Goodman MJ, Fishman PA, Hornbrook MC, O'Keeffe-Rosetti MC, Bachman DJ. Using risk-adjustment models to identify high-cost risks. Med Care. 2003;41(11):1301-12.
34. Welch CA, Czerwinski D, Ghimire B, Bertsimas D. Depression and costs of health care. Psychosomatics. 2009;50(4):392-401.
35. Dodd S, Bassi A, Bodger K, Williamson P. A comparison of multivariable regression models to analyse cost data. J Eval Clin Pract. 2006;12(1):76-86.
36. Skrepnek GH. Regression methods in the empiric analysis of health care data. J Manag Care Pharm. 2005;11(3):240-51.
37. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125-44.
38. Gerkens S, Nechelput M, Annemans L, et al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat. 2007;14(8):523-36.